ClinicalTrials.gg
Not yet recruitingNCT07524413Updated Oct 27, 2026

Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma

A Phase 2 interventional study of Becotatug Vedotin and Pucotenlimab in Nasopharyngeal Cancinoma (NPC) and Nasopharyngeal Cancer, sponsored by Sun Yat-sen University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 27, 2026Start date movedPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
298
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Nasopharyngeal Neoplasms by Sun Yat-sen University — 10 open to participants now, 15 under way, 7 of them phase 3. Nasopharyngeal Neoplasms · Sun Yat-sen University.

Planned enrollment
16th of 35
298 · median 228
Started
2026
with 4 others
Phase 2
16 of 38
3 open now
Primary completion
2031-12
later than 13 of 14 live
Registered
37th of 38
by date

Among the 38 studies in Nasopharyngeal Neoplasms by Sun Yat-sen University, this one is the 16th largest by planned enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 13 of the 14 other live ones, and was the 37th registered.

Nasopharyngeal Neoplasms

226 studies on the registry are indexed under Nasopharyngeal Neoplasms; 42 are open to participants now.

Browse Nasopharyngeal Neoplasms studies →

Open to participants now

10 of the 38 studies in Nasopharyngeal Neoplasms by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 32 Nasopharyngeal Neoplasms studies recruiting now, 9 (28%) set no upper age limit and 18 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Nasopharyngeal Neoplasms by Sun Yat-sen University, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy with becotatug vedotin (MRG003) plus pucotenlimab, followed by treatment allocation based on post-induction plasma cell-free Epstein-Barr virus DNA (cfEBV DNA) status and radiographic response in patients with locoregionally advanced nasopharyngeal carcinoma.

All participants will receive three cycles of induction therapy with becotatug vedotin (MRG003) plus the PD-1 inhibitor pucotenlimab. After induction therapy, participants with cfEBV DNA clearance and a complete or partial response will be classified as low risk and receive intensity-modulated radiotherapy alone, followed by adjuvant pucotenlimab. Participants without cfEBV DNA clearance or with stable or progressive disease will be classified as high risk and receive intensity-modulated radiotherapy with concurrent cisplatin, followed by adjuvant pucotenlimab and capecitabine.

The primary objectives are to evaluate the post-induction therapy complete response rate in the overall study population and event-free survival in the high-risk group.

Read the detailed description

This is a multicenter, prospective study evaluating a biomarker- and response-guided risk-adapted treatment strategy for locoregionally advanced nasopharyngeal carcinoma.

All participants will receive three cycles of induction therapy with becotatug vedotin (MRG003), an epidermal growth factor receptor-directed antibody-drug conjugate, plus the PD-1 inhibitor pucotenlimab. Risk assignment will be performed after completion of induction therapy using both plasma cell-free Epstein-Barr virus DNA (cfEBV DNA) status and radiographic tumor response.

Participants with undetectable cfEBV DNA and a complete or partial response after induction therapy will be assigned to the low-risk group. These participants will then receive intensity-modulated radiotherapy without concurrent cisplatin, followed by adjuvant pucotenlimab.

Participants with detectable cfEBV DNA after induction therapy, or whose best radiographic response is stable or progressive disease, will be assigned to the high-risk group. These participants will receive intensity-modulated radiotherapy with concurrent cisplatin, followed by adjuvant pucotenlimab and capecitabine.

The study has two primary objectives: to evaluate the complete response rate after induction therapy in the overall study population and to evaluate event-free survival in the higher-risk group. Secondary evaluations include overall survival, distant metastasis-free survival, locoregional recurrence-free survival, cfEBV DNA clearance after induction therapy, safety, tolerability, and patient-reported quality of life.

Exploratory analyses will investigate potential prognostic and treatment-response biomarkers in tumor tissue, blood, and stool samples. Clinical outcomes will also be explored across subgroups defined by age, sex, baseline cfEBV DNA level, percentage reduction or clearance of cfEBV DNA, clinical stage, and other relevant prognostic factors.

03

Conditions studied

  • Nasopharyngeal Cancinoma (NPC)
  • Nasopharyngeal Cancer

Keywords

  • PD-1 antibody
  • Antibody-Drug Conjugate
  • MRG003
  • Becotatug Vedotin
  • Pucotenlimab
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years at diagnosis, regardless of sex.
  2. Previously untreated nasopharyngeal carcinoma confirmed as non-keratinizing carcinoma according to the World Health Organization (WHO) classification.
  3. Locoregionally advanced nasopharyngeal carcinoma classified as stage II or III, excluding T3N0-1 disease, according to the 9th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) clinical staging system.
  4. Positive plasma Epstein-Barr virus (EBV) DNA before initiation of treatment (> 0 copies/mL).
  5. At least one as defined by version 1.1 (RECIST v1.1).
  6. Willing to provide an archived tumor tissue specimen from the primary or lesion obtained within the previous 2 years or a fresh tumor tissue specimen. Participants who are unable to provide a tumor tissue specimen may still be enrolled at the investigator's discretion, provided all other eligibility criteria are met.
  7. (ECOG) performance status of 0 or 1 within 7 days before the first dose of study treatment.
  8. Adequate organ function meeting the following criteria, without blood transfusion, any hematopoietic growth factor, and/or thrombopoietic agent within the 4 weeks before the screening assessments:

    1. Hematology: (ANC) ≥ 1.5 × 10⁹/L; white blood cell count > 4 × 10⁹/L; > 90 g/L; and count > 100 × 10⁹/L.
    2. Hepatic and renal function: Serum total (TBIL) ≤ 1.5 × the (ULN); (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 × ULN; alkaline phosphatase (ALP) ≤ 2.5 × ULN; ≥ 60 mL/min; and urinary protein ≤ 2+ or ≤ 1,000 mg/24 hours.
    3. Coagulation: (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. Stable low-dose anticoagulant therapy, such as aspirin 100 mg/day, is permitted.
  9. Normal results for thyroid function, serum amylase and lipase, pituitary function, inflammatory and infectious markers, cardiac enzymes, and electrocardiography ():

    1. Patients aged > 50 years with a smoking history must have normal pulmonary function test results.
    2. Patients with ECG abnormalities or a history of cardiovascular disease that does not meet any condition listed in Exclusion Criterion 5 must additionally undergo myocardial function testing and echocardiography, with normal results required for enrollment.
  10. Patients must provide written and be willing and able to comply with all protocol-specified follow-up visits, treatments, laboratory assessments, and other study requirements.
  11. Male patients with and women of must agree to use effective from the time of signing the informed consent form through 6 months after the last dose of study drug. Women of childbearing potential include premenopausal women and women who have been for less than 2 years. Women of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose of study drug.

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from the study:

  1. Current or previous history of another within the past 5 years, except for cured cervical carcinoma in situ, papillary thyroid carcinoma, or basal cell carcinoma of the skin.
  2. Negative plasma Epstein-Barr virus (EBV) DNA before initiation of treatment (= 0 copies/mL) or absence of pretreatment plasma EBV DNA testing.
  3. Prior receipt of any antitumor therapy for nasopharyngeal carcinoma or any of the following treatments:

    1. Any antibody-drug conjugate (ADC) containing a monomethyl auristatin E (MMAE) payload within 3 months before the first dose of study treatment.
    2. Any drug from another clinical trial within 28 days before the first dose of study treatment.
    3. Major surgery within 28 days before the first dose of study treatment without complete recovery, or planned major surgery within the first 12 weeks after initiation of study treatment.
  4. Positive antibody (HIV-Ab); active tuberculosis; active virus infection (HBV DNA > 1 × 10³ copies/mL); or positive virus antibody.
  5. History of primary immunodeficiency or active disease requiring agents or systemic therapy at a dose of ≥ 10 mg/day of prednisone or an equivalent corticosteroid within 2 weeks before enrollment. The following conditions or treatments are permitted: type 1 diabetes mellitus; hypothyroidism, including hypothyroidism caused by autoimmune thyroid disease, that is stable on hormone replacement therapy; psoriasis, vitiligo, or alopecia not requiring systemic treatment; topical or inhaled corticosteroids; or short-term systemic corticosteroid therapy lasting ≤ 7 days for the prevention or treatment of non-autoimmune, non-recurrent allergic conditions.
  6. Uncontrolled cardiac disease, including any of the following:

    1. Heart failure of (NYHA) Class ≥ II.
    2. Unstable angina.
    3. Myocardial infarction within the past year.
    4. Prolonged , defined as QTc > 450 msec in males or > 470 msec in females; complete left bundle branch block; third-degree atrioventricular block; or supraventricular or ventricular arrhythmia requiring treatment or intervention.
  7. Hypertension inadequately controlled with two antihypertensive agents, defined as systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg.
  8. Poorly controlled blood glucose, defined as either of the following, or concurrent diabetic gangrene:

    1. Fasting blood glucose > 10 mmol/L on two occasions.
    2. (HbA1c) > 8%.
  9. History of noninfectious interstitial lung disease (ILD) or pneumonitis requiring corticosteroid treatment, including pulmonary fibrosis or radiation pneumonitis; current ILD or pneumonitis; or imaging findings at screening that cannot exclude suspected ILD or pneumonitis.
  10. Concurrent pulmonary disease causing clinically severe respiratory impairment, including but not limited to:

    1. Any underlying pulmonary disease, such as pulmonary embolism, severe asthma, or severe (COPD), occurring within 3 months before screening.
    2. Restrictive lung disease.
    3. History of or concurrent interstitial pneumonitis, radiation pneumonitis, severe COPD, severe pulmonary insufficiency, symptomatic bronchospasm, or a similar pulmonary condition.
  11. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening, including deep vein thrombosis, arterial thrombosis, or pulmonary embolism. Infusion catheter-related thrombosis is exempt.
  12. Pregnant or breastfeeding women. Pregnancy testing should be considered for sexually active women of .
  13. Known to any component of pucotenlimab or becotatug vedotin (MRG003), including histidine, histidine hydrochloride, sucrose, mannitol, or polysorbate 80; or a history of a Grade ≥ 3 hypersensitivity reaction to any macromolecular protein preparation or monoclonal antibody.
  14. Serious infection of (CTCAE) Grade > 2 within 4 weeks before the first dose of study treatment, including but not limited to severe pneumonia, bacteremia, sepsis, or tuberculosis.
  15. Peripheral neuropathy of Grade > 1.
  16. Receipt of a within 30 days before the first dose of becotatug vedotin (MRG003).
  17. Prior solid organ transplantation or hematopoietic stem cell transplantation (allo-HSCT).
  18. Any other condition judged by the investigator to potentially compromise patient safety or compliance, including but not limited to a serious medical condition requiring prompt treatment, including a psychiatric disorder; markedly abnormal laboratory findings; or other psychological, familial, or social high-risk factors.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
298 participants (estimated)

Study arms

  • Experimental
    Low-Risk Group

    Participants with undetectable plasma cfEBV DNA and a radiographic complete response or partial response after three cycles of induction therapy \[Becotatug Vedotin (MRG003) 2.0 mg/kg, intravenous infusion, Day 1 + Pucotenlimab 200 mg, intravenous infusion, Day 1; 3 cycles, Q3W\] are classified as low risk and receive the following treatment: Radiotherapy Alone: Intensity-modulated radiotherapy (IMRT), 70 Gy in 33 fractions, once daily, 5 days per week; Adjuvant Immunotherapy (5 cycles, Q3W): Pucotenlimab 200 mg, intravenous infusion, Day 1.

    Drug: Becotatug Vedotin · Drug: Pucotenlimab · Radiation: Intensity-Modulated Radiotherapy

  • Experimental
    High-Risk Group

    Participants with detectable plasma cfEBV DNA or a radiographic response of stable disease or progressive disease after three cycles of induction therapy \[Becotatug Vedotin (MRG003) 2.0 mg/kg, intravenous infusion, Day 1 + Pucotenlimab 200 mg, intravenous infusion, Day 1; 3 cycles, Q3W\] are classified as high risk and receive the following treatment: Concurrent Chemoradiotherapy (CCRT): IMRT, 70 Gy in 33 fractions, once daily, 5 days per week + Cisplatin 100 mg/m², intravenous infusion, Day 1 (2 cycles, Q3W); Adjuvant Therapy: Pucotenlimab 200 mg, intravenous infusion, Day 1 (5 cycles, Q3W) + Capecitabine 650 mg/m², orally twice daily, Days 1-21 (17 cycles, Q3W).

    Drug: Becotatug Vedotin · Drug: Pucotenlimab · Radiation: Intensity-Modulated Radiotherapy · Drug: Cisplatin · Drug: Capecitabine

Interventions

  • Induction Therapy: Becotatug Vedotin (MRG003) 2.0 mg/kg, intravenous infusion, Day 1 (3 cycles, Q3W)

  • Induction Therapy: Pucotenlimab 200 mg, intravenous infusion, Day 1 (3 cycles, Q3W); Adjuvant Therapy: Pucotenlimab 200 mg, intravenous infusion, Day 1 (5 cycles, Q3W)

  • RadiationIntensity-Modulated Radiotherapy

    70 Gy in 33 fractions, once daily, 5 days per week

  • Concurrent Chemoradiotherapy: Cisplatin 100 mg/m², intravenous infusion, Day 1 (2 cycles, Q3W)

  • Adjuvant Therapy: Capecitabine 650 mg/m², orally twice daily, Days 1-21 (17 cycles, Q3W)

06

What researchers measure

Primary outcomes

  1. Post-induction Therapy Complete Response Rate (post-IT CRR)

    The proportion of patients achieving complete response following induction therapy

    Time frame: Within 9 to 21 days after the last dose of induction therapy

  2. Event-Free Survival (EFS) in the High-Risk Group

    The time from the date of enrollment to the first occurrence of locoregional recurrence, distant metastasis, or death from any cause.

    Time frame: 3 years & 5 years

Secondary outcomes

  1. Overall survival (OS)

    From date of enrollment to date of death from any cause

    Time frame: 3 years & 5 years

  2. Distant Metastasis-Free Survival (DMFS)

    From the date of enrollment to the date of first documented distant metastasis or death from any cause, whichever occurs first.

    Time frame: 3 years & 5 years

  3. Locoregional Recurrence-Free Survival (LRRFS)

    From the date of enrollment to the date of first documented locoregional recurrence or death from any cause, whichever occurs first.

    Time frame: 3 years & 5 years

  4. Adverse Events (AEs)

    Graded according to CTCAE V5.0

    Time frame: 3 years & 5 years

  5. Patient-Reported Adverse Events (PRO-CTCAE)

    Patient-reported adverse events will be assessed using selected items from the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE™), Chinese version, administered at each treatment cycle. Patients will self-report and rate the severity of relevant adverse events throughout the study treatment period.

    Time frame: At the end of each treatment cycle (each cycle is 21 days), from Cycle 1 of induction therapy through Cycle 5 of adjuvant therapy

  6. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score

    Assesses general quality of life in cancer patients. Items are scored and linearly transformed to a 0-100 scale. For functional scales, higher scores indicate better functioning; for symptom scales, higher scores indicate greater symptom burden.

    Time frame: At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy

  7. EORTC Quality of Life Questionnaire Head and Neck 35 (EORTC QLQ-H&N35, version 1)

    Assesses head and neck cancer-specific symptoms. Items are scored and linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms.

    Time frame: At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy

  8. Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N, Chinese version 4)

    Assesses quality of life specific to head and neck cancer patients. Items are rated on a 0-4 scale and summed to a total score of 0-156. Higher scores indicate better quality of life.

    Time frame: At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy

Other outcomes

  1. Correlation of Tumor, Peripheral Blood, and Fecal Biomarkers with Treatment Efficacy and Patient Prognosis

    Tumor tissue biomarkers: EGFR expression level, PD-L1 expression level, tumor-infiltrating lymphocyte (TIL) density, immune score, expression profiles of immune checkpoint molecules and immune cell subpopulations, and tumor cell transcriptomic gene expression; Peripheral blood biomarkers: Immune cell populations, immune repertoire, and cytokine profiles; Fecal biomarkers: Composition and characteristics of fecal biomarkers in relation to treatment response and prognosis

    Time frame: 3 years & 5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2031, 60 months later.

Of 33 phase 2 interventional studies under Nasopharyngeal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 124. This study's planned 60 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Apr 2026 → Dec 2026, primary completion Apr 2030 → Dec 2031 and completion Apr 2032 → Dec 2033.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 13, 2026
StartEst.
Dec 2026was Apr 2026
Primary completionEst.
Dec 2031was Apr 2030
CompletionEst.
Dec 2033was Apr 2032
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 2026→Dec 2026
Oct 27, 2026
Primary completion
Apr 2030→Dec 2031
Oct 27, 2026
Study completion
Apr 2032→Dec 2033
Oct 27, 2026
Enrollment
514→298
Oct 27, 2026
Eligibility
6 inclusion criteria edited, 9 added, 3 removed; 13 exclusion criteria edited, 17 added, 3 removed
What changed in the criteria
Inclusion criteria
  • Edited1. Age ≥ 18 years at the time of diagnosis, regardless of sex.
  • Removed2. Histologically confirmed newly diagnosed nasopharyngeal carcinoma (NPC) of non-keratinizing carcinoma histology (WHO classification)
  • Removed3. Locoregionally advanced NPC staged as T4N2 or T1-4N3 according to the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) 9th edition staging system. All patients must undergo the following evaluations prior to initiation of any treatment to confirm clinical staging: complete medical history and physical examination, complete blood count (CBC) and biochemistry panel, plasma Epstein-Barr virus (EBV) DNA titer and serology, nasopharyngoscopy, magnetic resonance imaging (MRI) of the head and neck, chest X-ray or computed tomography (CT) of the chest, abdominal ultrasound, and bone scintigraphy. 18F-fluorodeoxyglucose positron emission tomography/CT (¹⁸F-FDG PET/CT) may be used as a substitute for the latter three imaging modalities.
  • AddedPreviously untreated nasopharyngeal carcinoma histologically confirmed as non-keratinizing carcinoma according to the World Health Organization (WHO) classification.
  • AddedLocoregionally advanced nasopharyngeal carcinoma classified as stage II or III, excluding T3N0-1 disease, according to the 9th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) clinical staging system.
  • AddedPositive plasma Epstein-Barr virus (EBV) DNA before initiation of treatment (> 0 copies/mL).
  • Edited5. Willing to provide an archived tumor tissue (specimen from the primary or metastatic lesion, obtained within the previous 2 years prior to enrollment) oror a fresh biopsytumor tissue specimen. PatientsParticipants who are unable to provide a tumor tissue specimen may still be enrolled at the investigator's discretion, provided all other eligibility criteria are met.
  • Edited6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior tobefore the first dose of study treatment.
  • AddedAdequate organ function meeting the following criteria, without blood transfusion, any hematopoietic growth factor, and/or thrombopoietic agent within the 4 weeks before the screening assessments:
  • AddedHematology: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; white blood cell count > 4 × 10⁹/L; hemoglobin > 90 g/L; and platelet count > 100 × 10⁹/L.
  • Edited7. Adequate organ function, as defined by the following laboratory parameters, obtained within 4 weeks prior to screening, with no blood transfusions, hematopoietic growth factors, or thrombopoietic agents administered during this period: a) Hematology: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; white blood cell count > 4 × 10⁹/L; hemoglobin > 90 g/L; platelet count > 100 × 10⁹/L; b) Hepatic and renal function: Serum total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN); aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 × ULN; alkaline phosphatase (ALP) ≤ 2.5 × ULN; creatinine clearance ≥ 60 mL/min; and urinary protein ≤ 2+ or ≤ 10001,000 mg/24 hours; c) Coagulation: International normalized ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (patients receiving stable low-dose anticoagulation therapy, such as aspirin 100 mg/day, are permitted)
  • Removed8. Normal findings on thyroid function tests, serum amylase and lipase, pituitary function tests, inflammatory and infectious markers, cardiac enzyme panel, and electrocardiogram (ECG): a) Patients aged > 50 years with a smoking history must have normal pulmonary function test results; b) Patients with ECG abnormalities or a prior cardiovascular history (not meeting exclusion criteria) must additionally undergo myocardial function testing and echocardiography, with normal results required for enrollment
  • AddedCoagulation: International normalized ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. Stable low-dose anticoagulant therapy, such as aspirin 100 mg/day, is permitted.
  • AddedNormal results for thyroid function, serum amylase and lipase, pituitary function, inflammatory and infectious markers, cardiac enzymes, and electrocardiography (ECG):
  • AddedPatients aged > 50 years with a smoking history must have normal pulmonary function test results.
  • AddedPatients with ECG abnormalities or a history of cardiovascular disease that does not meet any condition listed in Exclusion Criterion 5 must additionally undergo myocardial function testing and echocardiography, with normal results required for enrollment.
  • Edited9. Willing and able toPatients must provide written informed consent and be willing and able to comply with all protocol-specified requirements, including scheduledfollow-up visits, treatment administrationtreatments, laboratory assessments, and other study proceduresrequirements.
  • Edited10. PatientsMale patients with reproductive potential and women of reproductivechildbearing potential must agree to use effective contraception from the time of signing the informed consent form through 6 months after the last dose of study treatmentdrug. Women of childbearing potential (WOCBP), defined asinclude premenopausal women and women withinwho have been postmenopausal for less than 2 years. Women of menopause,childbearing potential must have a negative serum pregnancy test within 7 days prior tobefore the first dose of study treatmentdrug.
Exclusion criteria
  • AddedPatients meeting any of the following criteria will be excluded from the study:
  • Edited1. HistoryCurrent or previous history of any otheranother malignancy within the past 5 years, with the exception of curatively treatedexcept for cured cervical carcinoma in situ, papillary thyroid carcinoma, or basal cell carcinoma of the skin.
  • Removed2. Prior receipt of any anti-tumor therapy for nasopharyngeal carcinoma, or any of the following: a) Any ADC drug with a monomethyl auristatin E (MMAE) payload within 3 months prior to first dose; b) Any investigational drug from another clinical trial within 28 days prior to first dose; c) Major surgery within 28 days prior to first dose without full recovery, or planned major surgery within the first 12 weeks after initiation of study treatment
  • AddedNegative plasma Epstein-Barr virus (EBV) DNA before initiation of treatment (= 0 copies/mL) or absence of pretreatment plasma EBV DNA testing.
  • AddedPrior receipt of any antitumor therapy for nasopharyngeal carcinoma or any of the following treatments:
  • AddedAny antibody-drug conjugate (ADC) containing a monomethyl auristatin E (MMAE) payload within 3 months before the first dose of study treatment.
  • AddedAny investigational drug from another clinical trial within 28 days before the first dose of study treatment.
  • AddedMajor surgery within 28 days before the first dose of study treatment without complete recovery, or planned major surgery within the first 12 weeks after initiation of study treatment.
  • Edited3. Positive human immunodeficiency virus antibody (HIV-Ab); active tuberculosis; active hepatitis B virus infection (HBV- DNA > 1 × 10³ copies/mL); or activepositive hepatitis C virus infection (HCV antibody positive and HCV-RNA above the lower limit of detection).
  • Edited4. History of primary immunodeficiency, or active autoimmune disease requiring immunosuppressive therapyagents or systemic corticosteroids (corticosteroid therapy at a dose of ≥ 10 mg/day of prednisone or an equivalent) corticosteroid within 2 weeks prior tobefore enrollment. The following conditions or treatments are exemptpermitted: type 1 diabetes mellitus; hypothyroidism (, including hypothyroidism caused by autoimmune thyroid disease), that is stable on hormone replacement therapy; psoriasis, vitiligo, or alopecia not requiring systemic treatment; and use of topical or inhaled corticosteroids,; or short-term (systemic corticosteroid therapy lasting ≤ 7 days) systemic corticosteroids for prophylaxisthe prevention or treatment of non-autoimmune, non-recurrent allergic conditions.
  • AddedUncontrolled cardiac disease, including any of the following:
  • AddedHeart failure of New York Heart Association (NYHA) Class ≥ II.
  • AddedUnstable angina.
  • AddedMyocardial infarction within the past year.
  • Edited5. Uncontrolled cardiac disease, including any of the following: (1) heart failure of New York Heart Association (NYHA) Class ≥ 2; (2) unstable angina; (3) myocardial infarction within the past 1 year; (4) prolongedProlonged QT interval (, defined as QTc > 450 msmsec in males or QTc > 470 msmsec in females),; complete left bundle branch block,; third-degree atrioventricular block,; or supraventricular or ventricular arrhythmia requiring treatment or intervention.
  • Edited6. Hypertension inadequately controlled with two antihypertensive agents (, defined as systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg).
  • Removed7. Poorly controlled blood glucose, defined as: (a) fasting blood glucose > 10 mmol/L on two occasions, or (b) glycated hemoglobin (HbA1c) > 8%; or concurrent diabetic gangrene
  • AddedPoorly controlled blood glucose, defined as either of the following, or concurrent diabetic gangrene:
  • AddedFasting blood glucose > 10 mmol/L on two occasions.
  • AddedGlycated hemoglobin (HbA1c) > 8%.
  • Edited8. History of noninfectious interstitial lung disease (ILD) or pulmonary inflammationpneumonitis requiring steroidcorticosteroid treatment (, including pulmonary fibrosis andor radiation pneumonitis),; current ILD or pulmonary inflammation,pneumonitis; or imaging findings at screening that cannot exclude suspected ILD or pulmonary inflammationpneumonitis.
  • Removed9. Concurrent pulmonary disease causing clinically severe respiratory impairment, including but not limited to: (a) any underlying pulmonary condition (e.g., pulmonary embolism, severe asthma, or severe chronic obstructive pulmonary disease [COPD] within 3 months prior to screening); (b) restrictive lung disease; (c) history of or concurrent interstitial pneumonitis, radiation pneumonitis, severe COPD, severe pulmonary insufficiency, or symptomatic bronchospasm

…and 11 more changes, on the record history on ClinicalTrials.gov ↗

Oct 27, 2026
Interventions
Added Drug: Capecitabine; removed Drug: Gemcitabine + cisplatin (GP). Arms added: Low-Risk Group·High-Risk Group; arms removed: ADC + PD-1Inhibitor Induction Therapy·GP + PD-1 Inhibitor Induction Therapy
Oct 27, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedEvent-Free Survival (EFS) in the High-Risk GroupTime frame: 3 years & 5 years
Oct 27, 2026
Secondary outcomes
4 time frame changed, 2 description edited
What changed in the outcomes
  • Time framePatient-Reported Adverse Events (PRO-CTCAE)At the end of each treatment cycle (each cycle is 21 days), from Cycle 1 of induction therapy through Cycle 6 of adjuvant therapy → At the end of each treatment cycle (each cycle is 21 days), from Cycle 1 of induction therapy through Cycle 5 of adjuvant therapy
  • Time frameEuropean Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) ScoreAt baseline, after completion of induction therapy (Week 10), mid-IMRT(Week 16), after completion of IMRT (Week 19), at the last adjuvant cycle (Week 34; each cycle is 21 days), and at 3, 12, 24, 36, 48, and 60 months post-radiotherapy → At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy
  • Time frameEORTC Quality of Life Questionnaire Head and Neck 35 (EORTC QLQ-H&N35, version 1)At baseline, after completion of induction therapy (Week 10), mid-IMRT(Week 16), after completion of IMRT (Week 19), at the last adjuvant cycle (Week 34; each cycle is 21 days), and at 3, 12, 24, 36, 48, and 60 months post-radiotherapy → At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy
  • Time frameFunctional Assessment of Cancer Therapy - Head and Neck (FACT-H&N, Chinese version 4)At baseline, after completion of induction therapy (Week 10), mid-IMRT(Week 16), after completion of IMRT (Week 19), at the last adjuvant cycle (Week 34; each cycle is 21 days), and at 3, 12, 24, 36, 48, and 60 months post-radiotherapy → At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy
  • DescriptionDistant Metastasis-Free Survival (DMFS): how it is measured was reworded
  • DescriptionLocoregional Recurrence-Free Survival (LRRFS): how it is measured was reworded
Oct 27, 2026
Title
Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) WithPlus PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
Oct 27, 2026
Design
Phase 3→Phase 2
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Start date Apr 2026→Dec 2026
    Primary completion Apr 2030→Dec 2031
    Study completion Apr 2032→Dec 2033
    Enrollment 514→298
    Eligibility 6 inclusion criteria edited, 9 added, 3 removed; 13 exclusion criteria edited, 17 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • Edited1. Age ≥ 18 years at the time of diagnosis, regardless of sex.
    • Removed2. Histologically confirmed newly diagnosed nasopharyngeal carcinoma (NPC) of non-keratinizing carcinoma histology (WHO classification)
    • Removed3. Locoregionally advanced NPC staged as T4N2 or T1-4N3 according to the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) 9th edition staging system. All patients must undergo the following evaluations prior to initiation of any treatment to confirm clinical staging: complete medical history and physical examination, complete blood count (CBC) and biochemistry panel, plasma Epstein-Barr virus (EBV) DNA titer and serology, nasopharyngoscopy, magnetic resonance imaging (MRI) of the head and neck, chest X-ray or computed tomography (CT) of the chest, abdominal ultrasound, and bone scintigraphy. 18F-fluorodeoxyglucose positron emission tomography/CT (¹⁸F-FDG PET/CT) may be used as a substitute for the latter three imaging modalities.
    • AddedPreviously untreated nasopharyngeal carcinoma histologically confirmed as non-keratinizing carcinoma according to the World Health Organization (WHO) classification.
    • AddedLocoregionally advanced nasopharyngeal carcinoma classified as stage II or III, excluding T3N0-1 disease, according to the 9th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) clinical staging system.
    • AddedPositive plasma Epstein-Barr virus (EBV) DNA before initiation of treatment (> 0 copies/mL).
    • Edited5. Willing to provide an archived tumor tissue (specimen from the primary or metastatic lesion, obtained within the previous 2 years prior to enrollment) oror a fresh biopsytumor tissue specimen. PatientsParticipants who are unable to provide a tumor tissue specimen may still be enrolled at the investigator's discretion, provided all other eligibility criteria are met.
    • Edited6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior tobefore the first dose of study treatment.
    • AddedAdequate organ function meeting the following criteria, without blood transfusion, any hematopoietic growth factor, and/or thrombopoietic agent within the 4 weeks before the screening assessments:
    • AddedHematology: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; white blood cell count > 4 × 10⁹/L; hemoglobin > 90 g/L; and platelet count > 100 × 10⁹/L.
    • Edited7. Adequate organ function, as defined by the following laboratory parameters, obtained within 4 weeks prior to screening, with no blood transfusions, hematopoietic growth factors, or thrombopoietic agents administered during this period: a) Hematology: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; white blood cell count > 4 × 10⁹/L; hemoglobin > 90 g/L; platelet count > 100 × 10⁹/L; b) Hepatic and renal function: Serum total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN); aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 × ULN; alkaline phosphatase (ALP) ≤ 2.5 × ULN; creatinine clearance ≥ 60 mL/min; and urinary protein ≤ 2+ or ≤ 10001,000 mg/24 hours; c) Coagulation: International normalized ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (patients receiving stable low-dose anticoagulation therapy, such as aspirin 100 mg/day, are permitted)
    • Removed8. Normal findings on thyroid function tests, serum amylase and lipase, pituitary function tests, inflammatory and infectious markers, cardiac enzyme panel, and electrocardiogram (ECG): a) Patients aged > 50 years with a smoking history must have normal pulmonary function test results; b) Patients with ECG abnormalities or a prior cardiovascular history (not meeting exclusion criteria) must additionally undergo myocardial function testing and echocardiography, with normal results required for enrollment
    • AddedCoagulation: International normalized ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. Stable low-dose anticoagulant therapy, such as aspirin 100 mg/day, is permitted.
    • AddedNormal results for thyroid function, serum amylase and lipase, pituitary function, inflammatory and infectious markers, cardiac enzymes, and electrocardiography (ECG):
    • AddedPatients aged > 50 years with a smoking history must have normal pulmonary function test results.
    • AddedPatients with ECG abnormalities or a history of cardiovascular disease that does not meet any condition listed in Exclusion Criterion 5 must additionally undergo myocardial function testing and echocardiography, with normal results required for enrollment.
    • Edited9. Willing and able toPatients must provide written informed consent and be willing and able to comply with all protocol-specified requirements, including scheduledfollow-up visits, treatment administrationtreatments, laboratory assessments, and other study proceduresrequirements.
    • Edited10. PatientsMale patients with reproductive potential and women of reproductivechildbearing potential must agree to use effective contraception from the time of signing the informed consent form through 6 months after the last dose of study treatmentdrug. Women of childbearing potential (WOCBP), defined asinclude premenopausal women and women withinwho have been postmenopausal for less than 2 years. Women of menopause,childbearing potential must have a negative serum pregnancy test within 7 days prior tobefore the first dose of study treatmentdrug.
    Exclusion criteria
    • AddedPatients meeting any of the following criteria will be excluded from the study:
    • Edited1. HistoryCurrent or previous history of any otheranother malignancy within the past 5 years, with the exception of curatively treatedexcept for cured cervical carcinoma in situ, papillary thyroid carcinoma, or basal cell carcinoma of the skin.
    • Removed2. Prior receipt of any anti-tumor therapy for nasopharyngeal carcinoma, or any of the following: a) Any ADC drug with a monomethyl auristatin E (MMAE) payload within 3 months prior to first dose; b) Any investigational drug from another clinical trial within 28 days prior to first dose; c) Major surgery within 28 days prior to first dose without full recovery, or planned major surgery within the first 12 weeks after initiation of study treatment
    • AddedNegative plasma Epstein-Barr virus (EBV) DNA before initiation of treatment (= 0 copies/mL) or absence of pretreatment plasma EBV DNA testing.
    • AddedPrior receipt of any antitumor therapy for nasopharyngeal carcinoma or any of the following treatments:
    • AddedAny antibody-drug conjugate (ADC) containing a monomethyl auristatin E (MMAE) payload within 3 months before the first dose of study treatment.
    • AddedAny investigational drug from another clinical trial within 28 days before the first dose of study treatment.
    • AddedMajor surgery within 28 days before the first dose of study treatment without complete recovery, or planned major surgery within the first 12 weeks after initiation of study treatment.
    • Edited3. Positive human immunodeficiency virus antibody (HIV-Ab); active tuberculosis; active hepatitis B virus infection (HBV- DNA > 1 × 10³ copies/mL); or activepositive hepatitis C virus infection (HCV antibody positive and HCV-RNA above the lower limit of detection).
    • Edited4. History of primary immunodeficiency, or active autoimmune disease requiring immunosuppressive therapyagents or systemic corticosteroids (corticosteroid therapy at a dose of ≥ 10 mg/day of prednisone or an equivalent) corticosteroid within 2 weeks prior tobefore enrollment. The following conditions or treatments are exemptpermitted: type 1 diabetes mellitus; hypothyroidism (, including hypothyroidism caused by autoimmune thyroid disease), that is stable on hormone replacement therapy; psoriasis, vitiligo, or alopecia not requiring systemic treatment; and use of topical or inhaled corticosteroids,; or short-term (systemic corticosteroid therapy lasting ≤ 7 days) systemic corticosteroids for prophylaxisthe prevention or treatment of non-autoimmune, non-recurrent allergic conditions.
    • AddedUncontrolled cardiac disease, including any of the following:
    • AddedHeart failure of New York Heart Association (NYHA) Class ≥ II.
    • AddedUnstable angina.
    • AddedMyocardial infarction within the past year.
    • Edited5. Uncontrolled cardiac disease, including any of the following: (1) heart failure of New York Heart Association (NYHA) Class ≥ 2; (2) unstable angina; (3) myocardial infarction within the past 1 year; (4) prolongedProlonged QT interval (, defined as QTc > 450 msmsec in males or QTc > 470 msmsec in females),; complete left bundle branch block,; third-degree atrioventricular block,; or supraventricular or ventricular arrhythmia requiring treatment or intervention.
    • Edited6. Hypertension inadequately controlled with two antihypertensive agents (, defined as systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg).
    • Removed7. Poorly controlled blood glucose, defined as: (a) fasting blood glucose > 10 mmol/L on two occasions, or (b) glycated hemoglobin (HbA1c) > 8%; or concurrent diabetic gangrene
    • AddedPoorly controlled blood glucose, defined as either of the following, or concurrent diabetic gangrene:
    • AddedFasting blood glucose > 10 mmol/L on two occasions.
    • AddedGlycated hemoglobin (HbA1c) > 8%.
    • Edited8. History of noninfectious interstitial lung disease (ILD) or pulmonary inflammationpneumonitis requiring steroidcorticosteroid treatment (, including pulmonary fibrosis andor radiation pneumonitis),; current ILD or pulmonary inflammation,pneumonitis; or imaging findings at screening that cannot exclude suspected ILD or pulmonary inflammationpneumonitis.
    • Removed9. Concurrent pulmonary disease causing clinically severe respiratory impairment, including but not limited to: (a) any underlying pulmonary condition (e.g., pulmonary embolism, severe asthma, or severe chronic obstructive pulmonary disease [COPD] within 3 months prior to screening); (b) restrictive lung disease; (c) history of or concurrent interstitial pneumonitis, radiation pneumonitis, severe COPD, severe pulmonary insufficiency, or symptomatic bronchospasm

    …and 11 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedEvent-Free Survival (EFS) in the High-Risk GroupTime frame: 3 years & 5 years
    Secondary outcomes 4 time frame changed, 2 description edited
    What changed in the outcomes
    • Time framePatient-Reported Adverse Events (PRO-CTCAE)At the end of each treatment cycle (each cycle is 21 days), from Cycle 1 of induction therapy through Cycle 6 of adjuvant therapy → At the end of each treatment cycle (each cycle is 21 days), from Cycle 1 of induction therapy through Cycle 5 of adjuvant therapy
    • Time frameEuropean Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) ScoreAt baseline, after completion of induction therapy (Week 10), mid-IMRT(Week 16), after completion of IMRT (Week 19), at the last adjuvant cycle (Week 34; each cycle is 21 days), and at 3, 12, 24, 36, 48, and 60 months post-radiotherapy → At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy
    • Time frameEORTC Quality of Life Questionnaire Head and Neck 35 (EORTC QLQ-H&N35, version 1)At baseline, after completion of induction therapy (Week 10), mid-IMRT(Week 16), after completion of IMRT (Week 19), at the last adjuvant cycle (Week 34; each cycle is 21 days), and at 3, 12, 24, 36, 48, and 60 months post-radiotherapy → At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy
    • Time frameFunctional Assessment of Cancer Therapy - Head and Neck (FACT-H&N, Chinese version 4)At baseline, after completion of induction therapy (Week 10), mid-IMRT(Week 16), after completion of IMRT (Week 19), at the last adjuvant cycle (Week 34; each cycle is 21 days), and at 3, 12, 24, 36, 48, and 60 months post-radiotherapy → At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy
    • DescriptionDistant Metastasis-Free Survival (DMFS): how it is measured was reworded
    • DescriptionLocoregional Recurrence-Free Survival (LRRFS): how it is measured was reworded
    Interventions Added Drug: Capecitabine; removed Drug: Gemcitabine + cisplatin (GP). Arms added: Low-Risk Group·High-Risk Group; arms removed: ADC + PD-1Inhibitor Induction Therapy·GP + PD-1 Inhibitor Induction Therapy
    Design Phase 3→Phase 2
    Title Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) WithPlus PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07524413
Responsible party
Jun Ma, MD (Professor, Sun Yat-sen University) — Principal investigator
First posted
Apr 13, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2031 (estimated)
Completion
Dec 2033 (estimated)
Last update
Oct 27, 2026

Study contacts

Jun Ma
Contact
majun2@mail.sysu.edu.cn
+862087343469
Wei Jiang
Contact
jiangwei@sysucc.org.cn
+862087342370

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Becotatug vedotin

Start the discussion